HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LT-171-861

Structure found in Figure 1A

Also Known As:

N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-4-(7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198

Experts

1.	Lu, Na: 2 articles (01/2021 - 01/2021)
2.	Zhao, Kai: 2 articles (01/2021 - 01/2021)
3.	Chen, Zhenzhong: 1 article (01/2021)
4.	Du, Jiaying: 1 article (01/2021)
5.	Guo, Qinglong: 1 article (01/2021)
6.	Hui, Hui: 1 article (01/2021)
7.	Huo, Tongxin: 1 article (01/2021)
8.	Kan, Shaoxin: 1 article (01/2021)
9.	Sun, Tifan: 1 article (01/2021)
10.	Wu, Tao: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "We also show the efficacy of LT‑171-861 in a subcutaneous implantation model and a bone marrow engrafted model in vivo, where administration of LT-171-861 led to almost complete tumor regression and increased survival. " 01/01/2021 - "Moreover, Olaparib, a PARP inhibitor, could enhance the antitumor effect of LT-171-861 in suppressing tumor growth in MM xenografted nude mice. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2021 - "LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia."
3.	Multiple Myeloma 01/01/2021 - "Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma."

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Poly(ADP-ribose) Polymerase Inhibitors
3.	olaparib